ATE517855T1 - Antikörper gegen chemotaktische monozytenproteine - Google Patents

Antikörper gegen chemotaktische monozytenproteine

Info

Publication number
ATE517855T1
ATE517855T1 AT02792310T AT02792310T ATE517855T1 AT E517855 T1 ATE517855 T1 AT E517855T1 AT 02792310 T AT02792310 T AT 02792310T AT 02792310 T AT02792310 T AT 02792310T AT E517855 T1 ATE517855 T1 AT E517855T1
Authority
AT
Austria
Prior art keywords
antibodies
monocyte proteins
chemotactic
chemotactic monocyte
proteins
Prior art date
Application number
AT02792310T
Other languages
English (en)
Inventor
Fougerolles Antonin De
Victor Kotelianski
Ellen Garber
Carl Reid
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE517855T1 publication Critical patent/ATE517855T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02792310T 2001-11-30 2002-11-27 Antikörper gegen chemotaktische monozytenproteine ATE517855T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34339101P 2001-11-30 2001-11-30
US38327702P 2002-05-24 2002-05-24
US40046902P 2002-08-01 2002-08-01
PCT/US2002/038229 WO2003048083A2 (en) 2001-11-30 2002-11-27 Antibodies against monocyte chemotactic proteins

Publications (1)

Publication Number Publication Date
ATE517855T1 true ATE517855T1 (de) 2011-08-15

Family

ID=27407563

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02792310T ATE517855T1 (de) 2001-11-30 2002-11-27 Antikörper gegen chemotaktische monozytenproteine

Country Status (8)

Country Link
US (6) US7405277B2 (de)
EP (3) EP2990394A1 (de)
AR (1) AR037456A1 (de)
AT (1) ATE517855T1 (de)
AU (1) AU2002357770B2 (de)
CA (1) CA2468733C (de)
DK (1) DK1461300T3 (de)
WO (1) WO2003048083A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR037456A1 (es) * 2001-11-30 2004-11-10 Biogen Inc Anticuerpos contra proteinas quimiotacticas monocitarias
WO2004016767A2 (en) * 2002-08-19 2004-02-26 The President And Fellows Of Harvard College Evolving new molecular function
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
WO2004045525A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
EP1567555A4 (de) * 2002-11-27 2006-06-21 Biogen Idec Inc Humanisierte antikörper gegen chemotaktische monozytenproteine
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
WO2005044200A2 (en) * 2003-11-05 2005-05-19 Centocor, Inc. Methods and compositions for treating mcp-1 related pathologies
DE602005017370D1 (de) * 2004-03-22 2009-12-10 Nuevolution As Ligationscodierung unter verwendung von oligonukleotidbausteinen
CA2566445C (en) 2004-05-12 2016-02-02 The Government Of The United States As Represented By The Secretary, Department Of Health And Human Services Methods related to the treatment of neurodegenerative and inflammatory conditions
AU2011265315B2 (en) * 2004-05-12 2014-08-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods related to the treatment of neurodegenerative and inflammatory conditions
CA2572289A1 (en) * 2004-06-30 2006-08-17 Centocor, Inc. Anti-mcp-1 antibodies, compositions, methods and uses
PE20061444A1 (es) * 2005-05-19 2007-01-15 Centocor Inc Anticuerpo anti-mcp-1, composiciones, metodos y usos
US8114964B2 (en) 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
WO2007142241A1 (ja) * 2006-06-05 2007-12-13 Hiroshima University 抗ｃｄ３８抗体を細胞表面に有する免疫担当細胞
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
MY149079A (en) * 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
WO2009001545A1 (ja) 2007-06-22 2008-12-31 Sapporo Medical University 移植片対宿主疾患の検査および治療方法
RU2547595C2 (ru) 2008-08-18 2015-04-10 Пфайзер Инк Антитела против ccr2
US20120269814A1 (en) * 2009-11-10 2012-10-25 Amgen Inc. Anti-c mpl antibodies
WO2011129382A1 (en) * 2010-04-16 2011-10-20 Abbott Japan Co. Ltd. Methods and reagents for diagnosing rheumatoid arthritis
GB201205739D0 (en) * 2012-03-30 2012-05-16 Ucl Business Plc Treatment of acute inflammation in the respiratory tract
US20150158942A1 (en) * 2012-05-22 2015-06-11 Shire Human Genetic Therapies, Inc. Anti-ccl2 antibodies for treatment of scleroderma
US9574004B2 (en) 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
PT3889181T (pt) 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
AU2014268316B2 (en) * 2013-05-23 2019-10-10 Takeda Pharmaceutical Company Limited Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
AU2015346150B2 (en) 2014-11-14 2021-08-19 Regeneron Pharmaceuticals, Inc. Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
JP6947372B2 (ja) * 2015-05-26 2021-10-13 学校法人東京薬科大学 炎症性腸疾患を抑制する抗体および該抗体を含む医薬組成物
HUE067888T2 (hu) 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
CA3079946A1 (en) 2017-10-30 2019-05-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
US11292847B2 (en) 2018-05-13 2022-04-05 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R inhibitor
EP3864042A1 (de) * 2018-10-11 2021-08-18 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Mittel und verfahren zum nachweis von sojaallergenen
CA3132587A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
EP3957324A4 (de) 2019-04-17 2023-02-08 Hiroshima University Therapeutikum für die urologische onkologie, dadurch gekennzeichnet, dass es in kombination mit il-6 -inhibitor und ccr2 -inhibitor verabreicht wird
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
WO2021026205A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0832981A1 (de) 1987-02-17 1998-04-01 Pharming B.V. DNA-Sequenzen die Proteine zwecks effizienter Abscheidung zur Milchdrüse leiten
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (de) 1991-06-14 2004-03-24 Genentech Inc. Verfahren zur Herstellung humanisierter Antikörper
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
JPH0967399A (ja) 1995-08-30 1997-03-11 Mitsui Toatsu Chem Inc 抗ｍｃｐ−１ヒトモノクローナル抗体
SE9600820D0 (sv) * 1996-03-01 1996-03-01 Pharmacia Ab Antibodies and their use
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
JP4398620B2 (ja) 2000-02-03 2010-01-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ヒト化抗ｃｃｒ−２抗体およびその使用方法
AU2001261743C9 (en) 2000-05-19 2006-07-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for reducing tumor growth and metastasis by inhibiting MCP-1 activity
US7309693B2 (en) 2000-05-26 2007-12-18 Kensuke Egashira Preventives and remedies for pulmonary hypertension
GB0016138D0 (en) 2000-06-30 2000-08-23 Novartis Ag Organic compounds
AR037456A1 (es) * 2001-11-30 2004-11-10 Biogen Inc Anticuerpos contra proteinas quimiotacticas monocitarias
EP1567555A4 (de) * 2002-11-27 2006-06-21 Biogen Idec Inc Humanisierte antikörper gegen chemotaktische monozytenproteine
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Also Published As

Publication number Publication date
WO2003048083A3 (en) 2004-01-15
EP1461300A2 (de) 2004-09-29
EP2298717A1 (de) 2011-03-23
EP1461300A4 (de) 2005-12-28
US20160185846A1 (en) 2016-06-30
US9096665B2 (en) 2015-08-04
US20090017028A1 (en) 2009-01-15
AU2002357770A1 (en) 2003-06-17
US7405277B2 (en) 2008-07-29
EP1461300B1 (de) 2011-07-27
DK1461300T3 (da) 2011-10-24
US7632501B2 (en) 2009-12-15
CA2468733C (en) 2013-06-11
US8431125B2 (en) 2013-04-30
CA2468733A1 (en) 2003-06-12
AR037456A1 (es) 2004-11-10
US7972597B2 (en) 2011-07-05
AU2002357770B2 (en) 2008-07-31
HK1155720A1 (en) 2012-05-25
US20120039873A1 (en) 2012-02-16
EP2298717B1 (de) 2015-10-28
US20050025768A1 (en) 2005-02-03
EP2990394A1 (de) 2016-03-02
WO2003048083A2 (en) 2003-06-12
US20140178382A1 (en) 2014-06-26
US20100166757A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
ATE517855T1 (de) Antikörper gegen chemotaktische monozytenproteine
DE60236735D1 (de) Antikörper gegen vla-1
DE60134148D1 (de) Antikörper gegen il-1 beta
EP1448787A4 (de) Menschliche monoklonale antikörper gegen dendritische zellen
EP1499352A4 (de) Rekombinante anti-interleukin-9-antikörper
NO20044347L (no) Anti-alfavbeta6-antistoff
NO2017058I1 (no) HPV 58 L1 protein
EP1396500A4 (de) Anti-trail-r-antikörper
DK1599504T3 (da) Modificeret antistof
NO2017012I1 (no) HPV 45 L1 protein
EP1616881A4 (de) Anti-mpl-antikörper
DE60222658D1 (de) Monoklonaler anti-cd-40-antikörper
DE602004022855D1 (de) Interleukin-10-antikörper
NO20023677D0 (no) Sementeringsmanifold-enhet
CY2012003I1 (el) Αντισωματα που συνδεονται ανοσοειδικως προς blys
NO20032612D0 (no) CXCR3-antagonister
ATE426616T1 (de) Antikírper gegen menschliches mcp-1
DE60210864D1 (de) Modifiziertes fluoreszentes Protein
DK1752470T3 (da) GAG-bindende proteiner
DE60127237D1 (de) Therapeutischer monoklonaler rekombinanter anti-ige antikörper gegen hunde-allergie
DE60129572D1 (de) Verwendung von antikörpern gegen spezifische mhc-peptidkomplexe
EE200300569A (et) CD44v6-spetsiifilised antikehad
FR2842873B1 (fr) Structure de carburateur
ATE513564T1 (de) Immunogener rekombinanter antikörper
EP1464701A4 (de) Fluoreszenzproteine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties